2023-10-26 ワシントン州立大学(WSU)
WSU researchers have developed a minifridge-sized bioreactor that is able to manufacture the cells, called T cells, at 95% of the maximum growth rate – about 30% faster than current technologies.
◆研究者は、牛のT細胞を使用してこのツールを開発し、ヒトのT細胞でも同様に機能すると予想しています。このツールは、従来の技術よりも約30%高速でT細胞を増殖させることができる、ミニ冷蔵庫サイズのバイオリアクターです。
◆免疫療法の使用は、T細胞の増殖にかかる費用と時間の制約により制限されています。現在、患者に250百万個のT細胞が必要であり、その需要に応えるためには新しいバイオマニュファクチャリングソリューションが必要です。この新しいバイオリアクターは、細胞が高速で増殖し、細胞ベースの治療の利用を増やすために貢献する可能性があります。
<関連情報>
- https://news.wsu.edu/press-release/2023/10/26/machine-can-quickly-produce-needed-cells-for-cancer-treatment/
- https://aiche.onlinelibrary.wiley.com/doi/10.1002/btpr.3388
がん免疫療法に用いるCD8細胞傷害性T細胞の迅速な増殖のための遠心バイオリアクターの開発 Development of a centrifugal bioreactor for rapid expansion of CD8 cytotoxic T cells for use in cancer immunotherapy
Kitana M. Kaiphanliam, Brenden Fraser-Hevlin, Eric S. Barrow, William C. Davis, Bernard J. Van Wie
Biotechnology Progress Published: 11 September 2023
DOI:https://doi.org/10.1002/btpr.3388
Abstract
One of the current difficulties limiting the use of adoptive cell therapy (ACT) for cancer treatment is the lack of methods for rapidly expanding T cells. As described in the present report, we developed a centrifugal bioreactor (CBR) that may resolve this manufacturing bottleneck. The CBR operates in perfusion by balancing centrifugal forces with a continuous feed of fresh medium, preventing cells from leaving the expansion culture chamber while maintaining nutrients for growth. A bovine CD8 cytotoxic T lymphocyte (CTL) cell line specific for an autologous target cell infected with a protozoan parasite, Theileria parva, was used to determine the efficacy of the CBR for ACT purposes. Batch culture experiments were conducted to predict how CTLs respond to environmental changes associated with consumption of nutrients and production of toxic metabolites, such as ammonium and lactate. Data from these studies were used to develop a kinetic growth model, allowing us to predict CTL growth in the CBR and determine the optimal operating parameters. The model predicts the maximum cell density the CBR can sustain is 5.5 × 107 cells/mL in a single 11-mL conical chamber with oxygen being the limiting factor. Experimental results expanding CTLs in the CBR are in 95% agreement with the kinetic model. The prototype CBR described in this report can be used to develop a CBR for use in cancer immunotherapy.
